148 related articles for article (PubMed ID: 2123160)
1. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
Vollenhoven BJ; Shekleton P; McDonald J; Healy DL
Fertil Steril; 1990 Dec; 54(6):1032-8. PubMed ID: 2123160
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
[TBL] [Abstract][Full Text] [Related]
3. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
Matta WH; Shaw RW; Nye M
Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
[TBL] [Abstract][Full Text] [Related]
5. Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment.
Kawamura N; Ito F; Ichimura T; Shibata S; Umesaki N; Ogita S
Fertil Steril; 1997 Oct; 68(4):632-6. PubMed ID: 9341601
[TBL] [Abstract][Full Text] [Related]
6. Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas.
Maheux R; Lemay A; Merat P
Fertil Steril; 1987 Feb; 47(2):229-33. PubMed ID: 3102282
[TBL] [Abstract][Full Text] [Related]
7. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid.
Loong EP; Wong FW
Fertil Steril; 1990 Sep; 54(3):530-1. PubMed ID: 2118862
[TBL] [Abstract][Full Text] [Related]
8. Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
McClelland HR; Quinn AJ
Ulster Med J; 1992 Apr; 61(1):51-5. PubMed ID: 1535743
[TBL] [Abstract][Full Text] [Related]
9. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
[TBL] [Abstract][Full Text] [Related]
10. Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment.
Fernández-Montolí ME; Díez-Gibert O; Samaniego JM; Balagueró L; Navarro MA
Fertil Steril; 1995 Mar; 63(3):522-7. PubMed ID: 7851581
[TBL] [Abstract][Full Text] [Related]
11. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
Maheux R; Lemay A; Turcot-Lemay L
Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
[TBL] [Abstract][Full Text] [Related]
12. [Shrinkage of uterine leiomyomas after intranasal administration of a LHRH agonist].
Uemura T; Kimura A; Shirasu K; Minaguchi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):365-8. PubMed ID: 2499643
[No Abstract] [Full Text] [Related]
13. [GnRH-analogs in the therapy of uterine myomatosis].
Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
[TBL] [Abstract][Full Text] [Related]
14. Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist.
Healy DL; Fraser HM; Lawson SL
Br Med J (Clin Res Ed); 1984 Nov; 289(6454):1267-8. PubMed ID: 6437510
[No Abstract] [Full Text] [Related]
15. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
[TBL] [Abstract][Full Text] [Related]
16. Infarcted intramural uterine leiomyomata during buserelin acetate treatment.
Chang MY; Tsai FB; Soong YK
Changgeng Yi Xue Za Zhi; 1993 Jun; 16(2):129-32. PubMed ID: 8339156
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Am J Obstet Gynecol; 1985 Aug; 152(8):1034-8. PubMed ID: 3927734
[TBL] [Abstract][Full Text] [Related]
18. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin.
Matta WH; Stabile I; Shaw RW; Campbell S
Fertil Steril; 1988 Jun; 49(6):1083-5. PubMed ID: 2967195
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of LHRH analogue action in uterine fibroids.
Shaw RW
Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
[TBL] [Abstract][Full Text] [Related]
20. Pelvic pain complicating LHRH analogue treatment of fibroids.
Chipato T; Healy DL; Vollenhoven B; Buckler HM
Aust N Z J Obstet Gynaecol; 1991 Nov; 31(4):383-4. PubMed ID: 1799362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
